secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0000939767-22-000029
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis files new patent infringement suit against MSN over generic CABOMETYX
------------------------------------------------------------------------------

- Filed complaint in Delaware asserting infringement of three new patents (11,091,439; 11,091,440; 11,098,015) related to cabozantinib.
- MSN amended its ANDA for generic CABOMETYX tablets (20/40/60 mg); Exelixis seeks injunction and approval date no earlier than patent expiration (latest Jan 15, 2030).
- This new case is separate from the 2019/2020 MSN ANDA Actions, which are scheduled for trial in May 2022.
- Exelixis also seeks order that FDA approval of MSN's ANDA be delayed until after patent expirations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000029/0000939767-22-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000029/exel-20220223.htm
  HTML page:      https://secwatch.observer/filing/0000939767-22-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer